Literature DB >> 22187258

Toxic epidermal necrolysis with ocular involvement following vaccination for hemorrhagic fever with renal syndrome.

Young Hoon Hwang1, Myung Seung Kang, Kyung O Lim, Sang Mok Lee.   

Abstract

We report a case of toxic epidermal necrolysis with ocular involvement following vaccination for hemorrhagic fever with renal syndrome. A healthy 20-year-old male soldier presented with confluent purpuric and erythematous dusky red macules evolving to flaccid blister and epidermal detachment on the whole body with conjunctival injection. The patient had no antecedent medical or surgical conditions except for two doses of hemorrhagic fever with renal syndrome vaccination. With supportive care, skin lesions were improved. Ophthalmic examinations revealed conjunctival injection with epithelial defects in both eyes. Ocular complications were resolved after amniotic membrane transplantation. Toxic epidermal necrolysis may be considered as a possible complication of hemorrhagic fever with renal syndrome vaccination.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22187258      PMCID: PMC3250336          DOI: 10.3349/ymj.2012.53.1.228

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  14 in total

1.  Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system.

Authors:  R Ball; L K Ball; R P Wise; M M Braun; J A Beeler; M E Salive
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

2.  Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.

Authors:  Yi-Sheng Chang; Fu-Chin Huang; Sung-Huei Tseng; Chao-Kai Hsu; Chung-Liang Ho; Hamm-Ming Sheu
Journal:  Cornea       Date:  2007-02       Impact factor: 2.651

3.  Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients.

Authors:  J Revuz; D Penso; J C Roujeau; J C Guillaume; C R Payne; J Wechsler; R Touraine
Journal:  Arch Dermatol       Date:  1987-09

4.  Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): consideration of active immunization in South Korea.

Authors:  Y M Sohn; H O Rho; M S Park; J S Kim; P L Summers
Journal:  Yonsei Med J       Date:  2001-06       Impact factor: 2.759

5.  Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis.

Authors:  Jose Santiago López-García; Luis Rivas Jara; Carmen Isabel García-Lozano; Eduardo Conesa; Isabel Elosua de Juan; Juan Murube del Castillo
Journal:  Ophthalmology       Date:  2010-09-29       Impact factor: 12.079

6.  Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum.

Authors:  W J Power; M Ghoraishi; J Merayo-Lloves; R A Neves; C S Foster
Journal:  Ophthalmology       Date:  1995-11       Impact factor: 12.079

7.  Stevens-Johnson syndrome after immunization with smallpox, anthrax, and tetanus vaccines.

Authors:  Ashish Chopra; Lisa A Drage; Eric M Hanson; Nicole L Touchet
Journal:  Mayo Clin Proc       Date:  2004-09       Impact factor: 7.616

8.  Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Julie Gueudry; Jean-Claude Roujeau; Michel Binaghi; Gisèle Soubrane; Marc Muraine
Journal:  Arch Dermatol       Date:  2009-02

Review 9.  Hantavirus infection: a review and global update.

Authors:  Zhenqiang Bi; Pierre B H Formenty; Cathy E Roth
Journal:  J Infect Dev Ctries       Date:  2008-02-01       Impact factor: 0.968

10.  Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.

Authors:  Chie Sotozono; Mayumi Ueta; Noriko Koizumi; Tsutomu Inatomi; Yuji Shirakata; Zenro Ikezawa; Koji Hashimoto; Shigeru Kinoshita
Journal:  Ophthalmology       Date:  2009-02-25       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.